Editorial: Translational research in the diagnosis and development of therapeutics for peritoneal surface malignancies.
作者信息
Chia Claramae Shulyn, Li Yan, Ceelen Wim, Ong Chin-Ann Johnny
机构信息
Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore.
出版信息
Front Oncol. 2023 Jul 10;13:1232993. doi: 10.3389/fonc.2023.1232993. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Translational research in the diagnosis and development of therapeutics for peritoneal surface malignancies.
Front Oncol. 2023 Jul 10;13:1232993. doi: 10.3389/fonc.2023.1232993. eCollection 2023.
2
Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.
J Clin Med. 2022 May 18;11(10):2840. doi: 10.3390/jcm11102840.
3
Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study.
World J Surg Oncol. 2019 Nov 6;17(1):182. doi: 10.1186/s12957-019-1731-4.
4
Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies).
Ann Surg Oncol. 2013 Aug;20(8):2655-62. doi: 10.1245/s10434-013-2933-6. Epub 2013 Mar 22.
5
Evolution of management in peritoneal surface malignancies.
Ulus Cerrahi Derg. 2015 Sep 1;32(3):203-7. doi: 10.5152/UCD.2016.3375. eCollection 2016.
6
Attitudes, knowledge & awareness amongst physicians in the management of peritoneal-surface based malignancies.
Asian J Surg. 2022 Dec;45(12):2829-2831. doi: 10.1016/j.asjsur.2022.06.054. Epub 2022 Jun 24.
7
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.
Int J Cancer. 2013 Sep 15;133(6):1497-506. doi: 10.1002/ijc.28158. Epub 2013 Apr 17.
8
Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies.
Am J Surg. 2014 Mar;207(3):403-7; discussion 406-7. doi: 10.1016/j.amjsurg.2013.09.021. Epub 2013 Dec 25.
9
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications.
Cancers (Basel). 2021 Feb 25;13(5):963. doi: 10.3390/cancers13050963.
10
A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis.
Surg Endosc. 2019 Mar;33(3):854-860. doi: 10.1007/s00464-018-6352-4. Epub 2018 Jul 12.
本文引用的文献
1
Molecular characterization of colorectal cancer related peritoneal metastatic disease.
Nat Commun. 2022 Aug 4;13(1):4443. doi: 10.1038/s41467-022-32198-z.
2
Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.
J Clin Oncol. 2022 Aug 20;40(24):2830. doi: 10.1200/JCO.21.02745. Epub 2022 Jun 1.
3
GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
BMC Cancer. 2022 May 12;22(1):536. doi: 10.1186/s12885-022-09572-7.
4
Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis.
Cell Rep Med. 2022 Feb 15;3(2):100526. doi: 10.1016/j.xcrm.2022.100526.
5
Primary and metastatic peritoneal surface malignancies.
Nat Rev Dis Primers. 2021 Dec 16;7(1):91. doi: 10.1038/s41572-021-00326-6.
6
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18.
7
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Mol Cancer. 2016 Feb 12;15:13. doi: 10.1186/s12943-016-0497-3.
8
Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
PLoS One. 2015 Feb 6;10(2):e0118080. doi: 10.1371/journal.pone.0118080. eCollection 2015.
9
Peritoneal surface malignancies and regional treatment: a review of the literature.
Surg Oncol. 2012 Jun;21(2):87-94. doi: 10.1016/j.suronc.2010.12.001. Epub 2011 Jan 8.
10
Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
Cancer Res. 2006 Feb 15;66(4):2181-7. doi: 10.1158/0008-5472.CAN-05-3393.
Zotero 插件